Diligent Unveils New Agentic Capabilities in Diligent One to Power the Future of Governance, Risk and Compliance

 New capabilities help organizations move from fragmented information to confident action while keeping people in control

 

(BUSINESS WIRE)--Diligent, the AI leader in governance, risk and compliance (GRC) solutions, today announced a major enhancement to Diligent One, its native AI platform, at Gartner’s Enterprise Risk, Audit and Compliance Conference (ERAC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915941016/en/

“For many organizations, GRC work is slowed by fragmented systems, manual coordination and time-consuming reporting processes,” said Brian Stafford, President and CEO of Diligent. “Our latest agentic capabilities help teams cut through that complexity by connecting context, surfacing what matters and driving faster execution — while keeping governance and professional judgement at the center."

An orchestration agent that coordinates work and approvals

The orchestration agent in Diligent One gives GRC professionals a natural-language interface to coordinate audit and risk work. Instead of simply answering questions, it enables users to describe what they need, and routes work to the right specialized agents to execute workflows. Agents are built on Diligent One’s connected GRC data, giving them the domain knowledge to execute workflows across the audit and risk lifecycle, automating the work that slows practitioners down without replacing human judgement.

Through Diligent One, specialized agents:

Help risk teams move from periodic assessments to continuous management by working directly in Diligent Enterprise Risk Management. The agent monitors risk data, cleans records, coordinates assessments, follows up on overdue actions, escalates issues and surfaces emerging risks.

Help internal audit teams plan and execute audits faster by turning manual preparation into conversational workflows in Diligent Audit. The agent identifies relevant risks, maps them to audit objectives, links existing controls and supports evidence collection, testing and findings development.

In addition, AI reporting turns live risk and controls data into board-ready reports and insights on demand. Using conversational prompts or templates, teams can quickly surface key findings and generate polished, secure, source-cited reports in minutes instead of days — eliminating hours spent manually pulling together data, insights and presentations.

“Risk and audit teams are being asked to look beyond what happened yesterday and give the business the insights it needs to make better decisions today and tomorrow,” said Scott Bridgen, General Manager, Risk & Audit at Diligent. “That means moving from static, point-in-time reporting to always-on monitoring that can identify changes as they happen and trigger action in real time, with the right level of oversight, approval and accountability.”

AI that reasons like a GRC expert

At the foundation of Diligent One is the GRC brain, a connected intelligence layer that links regulations, obligations, policies, controls, risks, evidence and actions. By connecting this information, the GRC brain gives agents the domain knowledge to work like an experienced GRC practitioner, equipped with deep context of how information connects across the business.

This connected intelligence gives Diligent One’s agents the ability to reason across relationships to deliver sharper insights and clearly explain the rationale behind the recommendations. The result is practical, actionable intelligence that helps GRC teams prioritize work, surface potential gaps and respond more efficiently to emerging risks. The GRC brain will become available in select Diligent solutions in October.

Diligent is showcasing its latest agentic capabilities at Gartner ERAC in Dallas on September 15-16, Booth 201.

Learn more about Diligent’s AI capabilities at www.diligent.com/platform/diligent-ai

About Diligent

Diligent is the AI leader in governance, risk and compliance (GRC) solutions, helping more than 1 million users and 700,000 board members to clarify risk and elevate governance. The Diligent One Platform gives practitioners, the C-suite and the board a consolidated view of their entire GRC practice so they can more effectively manage risk, build greater resilience and make better decisions, faster. Learn more at diligent.com. Follow Diligent on LinkedIn and Facebook.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915941016/en/

Permalink

https://aetoswire.com/en/news/54604218

Contacts

 

Media

Michele Steinmetz

Senior Director, Marketing Communications, Diligent

+1-215-817-5610

msteinmetz@diligent.com

 

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

 OSAKA, Japan & CAMBRIDGE, Mass. -

2026 Awardees are Corus International, Humanity & Inclusion Handicap International, Kwame Nkrumah University of Science and Technology (KNUST) and Terre des hommes Foundation (Tdh)

Commitment of USD 22.2 Million Increases Takeda’s Total Global CSR Program Contributions to USD 260.9 Million Across 42 Diverse Collaborations Worldwide, With 20 Currently Ongoing in 42 Countries

 

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company’s purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting global aid priorities continue to challenge healthcare access, Takeda is advancing its 2026 collaborations with the goal of expanding equitable access, strengthening health system resilience and improving patient outcomes. These efforts focus on locally led solutions that enhance health infrastructure, prepare the healthcare workforce and leverage innovation to sustain essential services for climate-vulnerable communities.

“Takeda has made a generational promise to improve health, and for the last 10 years, our Global CSR Program has given our people a meaningful way to put that promise into practice,” said Giles Platford, president of the International Business Unit at Takeda. “Significant, sustainable impact takes more than a single investment. It requires working with local partners who understand the needs in their communities and can help strengthen the systems people rely on. We are proud to support this year’s awardees as they address the challenging effects of climate change on healthcare systems and patients.”

Takeda’s commitments to these new awardees in 2026 include:

USD 6.4 million to Corus International. Linking climate-adaptive early warning, resilient service delivery and disaster preparedness aiming to protect the continuity of essential health services in Nepal.

“Climate shocks are reshaping where and when diseases strike, and too often the communities with the least warning are most impacted,” said Daniel V. Speckhard, President & CEO of Corus International. “Thanks to Takeda's generous support and partnership, Corus will help communities in Nepal predict outbreaks before they spread, strengthen health facilities against climate disasters, and equip communities to respond early. Together, we're building an early warning model that will be sustained by government and can be scaled beyond Nepal.”

USD 6.1 million to Humanity & Inclusion Handicap International. Strengthening inclusive, climate-resilient health systems by increasing workforce capacity, community preparedness and accessible facility adaptation in Honduras and Peru.

“We are honored to be selected as a Takeda Global CSR Program FY2026 awardee,” said Manuel Patrouillard, General Director of Humanity and Inclusion Handicap International. “This project makes a stronger alliance to support communities facing climate-related health risks, especially children, older adults, and people with disabilities across Honduras and Peru.”

USD 5.1 million to Kwame Nkrumah University of Science and Technology (KNUST). Readying the pharmacy workforce as frontline workers, advancing climate-responsive care through capacity building and greener practices in Ghana.

“Takeda's support gives us an excellent opportunity to put pharmacists right at the heart of how we respond to climate change and health,” said Prof. Christian Agyare, Vice Chancellor of KNUST. “Through PharmAdapt project we will train our pharmacists, prepare them for emergencies, and build standards that will last well beyond this project. This partnership means KNUST, supported by Takeda, can lead the way in creating practical tools and lessons that other countries across West Africa, and beyond, can learn from.”

USD 4.6 million to Terre des hommes Foundation (TdH). Supporting the building of climate resilient primary healthcare through facility retrofits, early warning and community preparedness in Egypt and Lebanon.

“I am deeply grateful for Takeda’s support. This partnership represents an important investment in the health and resilience of vulnerable communities in Egypt and Lebanon, helping pregnant women, newborns, and children access climate-resilient and environmentally sustainable health services,” said Barbara Hintermann, Director General of Tdh. “This collaboration will generate critical evidence on what works, helping to shape scalable solutions and inform policies that strengthen health systems and safeguard children’s future in an increasingly climate-affected world.”

About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at https://www.sec.gov/. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917571464/en/

Permalink

https://www.aetoswire.com/en/news/1809202657412

Contacts

Tsuyoshi Tada (Tokyo)

toiawase_kouhou@takeda.co.jp

Kristi Bond (Boston)

Media_Relations@takeda.com

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces

 WASHINGTON - Saturday, 19. September 2026 AETOSWire  

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand.

 

(BUSINESS WIRE)--International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim.

Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide.

Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than USD 600 million) tied to a single currency exchange transaction of $150,000, a matter his legal team maintains has been mischaracterized in Thai media reporting.

"I have reviewed the facts of this case closely, and what I see is an unexplained level of enforcement that is wildly disproportionate to the underlying transaction," said Genser. "When a routine currency exchange leads to a freeze of this scale, when primary KYC responsibility properly sits with the regulated exchange rather than the end recipient, and when a six-year-old's savings account is drawn into proceedings with threats of detention, these are the kinds of due process questions the international community should be asking. I'm joining this effort because those questions deserve answers."

Genser's involvement adds an internationally recognized voice to a case that has drawn growing attention from investors, legal observers, and human rights advocates watching Thailand's use of its anti-money laundering and forfeiture powers.

Robert Seiden, founder of Seiden Law LLP and Yim Leak's chief global counsel, has represented a broad range of high-profile domestic and international clients across corporate, litigation, and reputational matters, including prior work for the Trump Organization.

Lanny J. Davis, an internationally renowned media spokesperson and defender of high-profile and private individuals targeted by reputational smears, who advised both Presidents Bill Clinton and George W. Bush, has joined Mr. Genser.

"We are looking closely at the Thai government's complicity, and indeed willful blindness, in allowing a Thailand-based clique to engage in a sustained campaign of lies and smears against Mr. Yim," said Davis, a globally recognized human rights advocate and former White House Special Counsel to the President. "Conduct like this raises serious human rights concerns." He added, "We will investigate, expose, and prosecute anyone who continues to abuse the media and governments for their own benefit."

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260918034322/en/

Permalink

https://www.aetoswire.com/en/news/1909202657423

Contacts

For media inquiries:

Contact Lanny Davis Public Relations at ldavis@lannyjdavis.com or +1 (202) 744-2792

 Doha, Qatar - Friday, 18. September 2026 AETOSWire Print 

 

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm.

As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs.

The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance operational efficiency, service quality and customer experience. All proposals will remain subject to feasibility studies, Shahba Bank Board decisions, relevant General Assembly approvals, and applicable regulatory and supervisory approvals.

Mr. Moutaz Al-Khayyat, Chairman of Estithmar Holding, said:

“This investment reflects our confidence in Syria’s economic potential and Estithmar Holding’s approach to pursuing strategic opportunities that contribute to sustainable growth. We have a long-term vision for Shahba Bank and aspire to strengthen its capabilities and support its continued development, enabling the Bank to deliver modern and effective banking services that meet the evolving needs of individuals and businesses, while supporting the Syrian economy.”

Mr. Mohammad Safwat Raslan, Governor of the Central Bank of Syria, said:

“The entry of new institutional investment into the Syrian banking sector represents a positive step towards strengthening the sector’s capabilities and its role in serving the national economy. We welcome credible investments that uphold strong standards of governance, compliance and risk management.

Mr. Basel Shaddad, CEO of Estithmar Holding, said:

“The Shahba Bank stake transfer is a decisive step that strengthens Estithmar Holding’s leadership in the region’s financial sector. With our market capitalization now above USD 5 billion, we are advancing our long-term investment strategy with strong confidence in Syria’s economic resurgence and in building institutions that support sustainable growth.”

Fadi Salim Al Faqih, Group CEO of Estithmar Capital, said:

“This investment marks the beginning of a new phase in our shareholding in Shahba Bank. Through Masaref Holding, we will work with the Bank’s Board of Directors and relevant governing bodies to assess initiatives and modern banking products and services that strengthen the Bank’s capabilities and serve the Syrian economy, in accordance with established governance frameworks.”

Permalink

https://www.aetoswire.com/en/news/esth1892026e

Contacts

Estithmar Holding

Aida Bouassida

media@estithmarholding.com

Former Colombian President Iván Duque Appointed to Advance ICC and Carbon Measures' Global Product-Level Carbon Accounting Initiative

 Duque will chair the ICC & Carbon Measures Technical Expert Panel Advisory Group, bringing policy, business and practitioner perspectives into the next phase of their work.

 

(BUSINESS WIRE)--The International Chamber of Commerce (ICC) and Carbon Measures today announced that Iván Duque Márquez, former President of Colombia, has been named Chair of the newly created Technical Expert Panel Advisory Group established to complement the work of the TEP on Carbon Accounting.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915635710/en/

The TEP, co-convened by ICC and Carbon Measures, brings together recognized experts from academia, financial accounting, industry and civil society to develop a globally applicable carbon emissions accounting framework. The TEP’s work comes amid growing global momentum toward harmonization of carbon accounting.

The Advisory Group was created to take the TEP’s technical work to the next level, broadening engagement with policymakers, business leaders, and other stakeholders.

While the TEP’s technical conclusions are completely independent, the Advisory Group chaired by former President of Colombia Iván Duque will advise and provide different external perspectives to that work, bringing together leaders from across sectors and geographies to provide strategic input, help ensure business relevance and real-world applicability.

Additional members of the Advisory Group will be announced in the coming months, bringing together diverse perspectives from across sectors and geographies as the TEP continues to advance its technical work.

"President Duque’s appointment marks an important step for this initiative. His leadership and experience will help us build engagement across key stakeholder groups – advancing the wider conversation on the potential utility of a globally consistent product-level carbon accounting regime," said Andrew Wilson, ICC Deputy Secretary General.

The Panel’s Guiding Principles and comprehensive Landscape Review establish a common foundation by assessing existing approaches and identifying where gaps remain. The next phase for the TEP’s work is to develop a globally applicable carbon accounting framework, building on the progress already made and drawing on the practical experience of professionals doing this work every day.

As Chair, Duque will help deepen engagement with business leaders, policymakers and practitioners. Drawing on his experience in government and economic development, he will foster opportunities for technical dialogue, active listening and co-creation around what implementation will require in practice.

“It is a great honor to join the Carbon Measures team and contribute to accelerating the advancement of the highest standards in climate accounting,” said Iván Duque, Chair of the TEP Advisory Group. “This will contribute to developing more and better projects, while enhancing transparency in the mobilization of capital toward decarbonization.”

Duque brings extensive experience across government, economic development and climate policy to the role. As President of Colombia from 2018 to 2022, his administration committed the country to reducing greenhouse gas emissions by 51% by 2030 and achieving carbon neutrality by 2050. Those commitments were subsequently enshrined in Colombia’s 2021 Climate Action Law. Previously, Duque spent more than a decade at the Inter-American Development Bank, and since leaving office has remained active on global climate, conservation and economic development issues through work with organizations including Conservation International, the Bezos Earth Fund and Concordia, where he launched the Concordia Amazon Initiative.

“Getting the technical work right is essential, but it’s only part of the equation. If we want to build a carbon accounting framework that works across real-world supply chains, we need input from businesses, policymakers and other leaders who understand how it needs to work on the ground,” said Amy Brachio, CEO of Carbon Measures. “President Duque understands firsthand how economic growth, public policy and climate action intersect. I’m thrilled to have him leading the Advisory Group and helping us bring more voices into the process as the TEP moves its work forward.”

About International Chamber of Commerce

The International Chamber of Commerce (ICC) is the institutional representative of more than 45 million companies in over 170 countries. ICC’s core mission is to make business work for everyone, every day, everywhere. Through a unique mix of advocacy, solutions and standard setting, we promote international trade, responsible business conduct and a global approach to regulation, in addition to providing market-leading dispute resolution services. Our members include many of the world’s leading companies, SMEs, business associations and local chambers of commerce.

About Carbon Measures

Carbon Measures is a global coalition of leading businesses committed to advancing a ledger-based carbon accounting framework that provides accurate, verifiable, and timely company- and product-level data. Additionally, Carbon Measures is calling for product-level carbon intensity policies that unlock innovation, competition and market-based solutions to reduce emissions. To learn more about Carbon Measures, please visit carbonmeasures.org.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915635710/en/

Permalink

https://www.aetoswire.com/en/news/1709202657383

Contacts

MEDIA CONTACTS

randa.eltahawy@iccwbo.org

media@carbonmeasures.org

Medisca Launches Global Peptide Division

 New division brings API-grade peptides and Medisca’s quality-first pharmaceutical expertise to a rapidly evolving area of personalized medicine

 

(BUSINESS WIRE)--Medisca today announced the launch of Medisca Peptides, a dedicated global division focused on expanding access to API-grade peptides and building an integrated peptide platform for pharmaceutical and personalized medicine markets worldwide. As the peptide landscape evolves, Medisca is proactively building the capabilities and infrastructure needed to support API-grade peptides within applicable regulatory frameworks.

The launch represents a significant long-term commitment to peptides, including the expansion of Medisca’s portfolio, strategic manufacturing relationships, and the pharmaceutical infrastructure needed to support the category’s growth. It also signals Medisca’s ambition to become a leading force in the next generation of peptide innovation.

For Medisca, the opportunity is familiar.

More than 35 years ago, the company was founded to help close the gap between the pharmaceutical standards compounders needed and the quality ingredients they could readily access. Today, as peptides emerge as an important area of pharmaceutical innovation and personalized medicine, Medisca sees another defining moment for the industry; one where quality, regulatory responsibility and responsible access will be critical to the category’s future.

The category is growing. Medisca intends to help define the standard.

“When I founded Medisca, I saw an opportunity to bring pharmaceutical compounding closer to the standards of traditional pharma by giving compounders better access to API-grade ingredients and holding those ingredients to a higher standard,” said Antonio Dos Santos, Founder and Chief Executive Officer of Medisca. “Today, I see a similar opportunity with peptides. We are not entering this space to follow it. We intend to help shape it.”

Defining a higher standard for peptide quality

Medisca’s approach begins at the source. The company has selected established manufacturing partners that share its quality-first mindset, prioritizing pharmaceutical experience, demonstrated quality systems, manufacturing expertise, and strong quality and compliance practices.

Medisca will apply established processes for manufacturer qualification, product testing, documentation and supply-chain oversight to the peptide APIs it brings to market. These controls are particularly important for peptides, where manufacturing complexity, characterization, purity, and peptide-related impurities present distinct quality considerations. Medisca is committed to operating within applicable regulatory frameworks and supporting responsible access to peptide APIs.

Building an Integrated Peptide Platform

Medisca Peptides extends beyond API supply, bringing together formulation expertise, compounding technologies and equipment, analytical services, education and technical support.

By connecting these capabilities within one platform, Medisca aims to support healthcare professionals and pharmaceutical partners with both the ingredients and expertise needed to navigate the evolving peptide landscape.

“Healthcare professionals and pharmaceutical partners need confidence in the quality and source of a peptide API, but they also need the expertise and infrastructure to put innovation into practice,” said Charlie Guerini, Chief Commercial Officer of Medisca. “That is what we are building with Medisca Peptides: an integrated platform that brings together a growing API portfolio, carefully selected manufacturing partners, reliable supply and the technical expertise our customers have trusted for decades.”

Shaping the Future of Peptide Innovation

The launch marks the beginning of a broader, multi-year strategy to establish Medisca as a global leader in peptide quality, supply and innovation.

Medisca will expand its peptide API portfolio and strategic manufacturing relationships while investing in the scientific, analytical, formulation, technical and educational capabilities needed to advance opportunities across pharmaceutical and personalized medicine.

Beyond supply, Medisca will take an active leadership role in shaping the future of peptides, advocating for added guardrails, transparency, responsible access and appropriate quality standards while working alongside manufacturers, healthcare professionals and industry stakeholders as science, regulation and clinical practice evolve.

The ambition is clear: to help define the next generation of peptides by bringing together the quality, expertise and integrated solutions needed to advance the category.

Medisca Peptides will begin rolling out across select global markets, with additional portfolio, strategic partnership and capability announcements to follow.

About Medisca

Founded in 1989, Medisca is a leader in personalized medicine and pharmaceutical supply chain solutions, with a vast portfolio of over 2,000 products completed by a library of 10,000+ proprietary and customized medication formulas, expertise and services in pharmaceutical compounding, continuing healthcare education, and analytical testing. Providing finely-tuned solutions to diverse wellness sectors in numerous markets globally, Medisca is bridging the gaps in healthcare and empowering personalized wellness for all. For more information, visit www.medisca.com and follow us on LinkedIn, Facebook, and YouTube.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917717977/en/

Permalink

https://www.aetoswire.com/en/news/1709202657395

Contacts

Medisca Communications

communications@medisca.com

1-800-665-6334

Brushing Well Is Harder Than Most People Think — New Research Confirms Why the Technology Behind Oral-B iO is the Best Way to Help You Get it Right

 GENEVA - Thursday, 17. September 2026

Ranked #1 for plaque removal and gingivitis reduction, Oral-B iO's oscillating-rotating technology, paired with its unique round brush head, delivers a superior clean that helps people brush better every day, remove more plaque, and improve their gum health for healthier teeth for life.

 

(BUSINESS WIRE)--Oral-B, the #1 toothbrush brand used and recommended by dentists worldwide, today announced new evidence reinforcing the superiority of Oral-B iO technology. In an independent 2026 peer-reviewed network meta-analysis of 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked #1 for plaque removal and gingivitis reduction.

Most people think they are brushing effectively, but brushing well is harder than it seems. Plaque often remains in the places that are hardest to clean, including along the gumline, between teeth and around molars. In fact, 80% of people miss at least one area when brushing, and 60% miss their molars. Over time, that plaque buildup can impact oral health and well-being.

“People brush every day, but brushing effectively in the areas that matter most is not always easy,” said Svetlana Farrell, DDS, PhD, Sr. Director, Oral Health Sciences & Professional Scientific Relations. "Oral-B iO was designed around a simple reality: brushing well is harder than most people think. It helps make a superior clean easier to achieve by guiding people to brush more thoroughly and with the right pressure."

The proof is clear: Oral-B iO cleans better

Across 19 randomized clinical studies involving more than 1,300 participants, the oscillating-rotating technology behind Oral-B iO was ranked first for plaque removal and gingivitis reduction in an independent 2026 peer-reviewed network meta-analysis.

The findings add to a broader body of evidence supporting Oral-B superiority, including more than 120 peer-reviewed publications on Oral-B round-head technology and cleaning performance.

Study after study confirms Oral-B iO technology cleans better, removing more plaque and helping people achieve healthier gums. Oral-B iO removes 100% more plaque than a manual toothbrush and delivers 100% healthier gums. Clinical evidence shows Oral-B iO helps 88% of people with early gum problems get back to healthy gums, four times more than manual brushing, and is 60% more effective than a premium sonic toothbrush along the gumline, where gum issues often persist.

“Effective plaque control is foundational to gum health, but many patients struggle to maintain the right technique, brushing time, pressure and coverage at home,” said Prof. Liran Levin, Professor of Periodontology and the Chair of the Department of Specialty Dentistry at the Northeast Ohio Medical University. “What stands out in this evidence is that Oral-B iO is not only shown to remove more plaque and support healthier gums, but also it is designed to help people brush thoroughly, use the right pressure and sustain better brushing every day. That is where innovation can make a meaningful difference between dental visits.”

Brushing well is harder than most people think and not all brushes, even power brushes, clean the same. Oral-B iO makes a superior clean easier.

Oral-B iO's superiority starts with its oscillating-rotating technology, paired with Oral-B's unique dentist-inspired round brush head, to make a superior clean easier to achieve. The round head surrounds and adapts to each tooth, helping remove plaque where it builds most. Synchronized rotations, micro-vibrations and smart pressure guidance help people brush more completely, clean thoroughly yet gently, avoid brushing too hard, and reach difficult-to-clean areas with less effort.

Simply by switching to iO, people already brush better: research shows 84% of people reached all inside surfaces of teeth after one week of use, significantly more than earlier research showing only 44% with manual brushing.

Better brushing habits start early

The challenge is even more important for children who are still learning how to brush effectively. Good oral-health habits start early, but children need help building the motivation, technique and twice-daily routine that make effective brushing easier to sustain over time.

Oral-B iO Kids helps make brushing easier and more engaging. In product-use research, 90% of children say they love brushing with Oral-B iO Kids, 84% of parents say their child is motivated to brush twice a day for two minutes, 83% of children say the toothbrush makes them want to brush more often, and 88% of children say Oral-B iO Kids makes it easy to brush all areas of their mouth.

Oral-B iO Kids removes 1.5x more plaque than a manual toothbrush, including in hard-to-clean molars, and is the only electric toothbrush technology to have earned the European Academy of Paediatric Dentistry, EAPD, Seal of Approval for children aged 3+.

“Between work, school, and activities, life gets hectic, and our daily routines don’t always match our best intentions,” said Dr. Jeanette MacLean, DDS, Diplomate, American Board of Pediatric Dentistry, Fellow, American Academy of Pediatric Dentistry. “As a pediatric dentist and a mom, I appreciate features that get kids more interested in brushing, help them take their time, and reach the spots they tend to miss. It’s a little extra help to support healthy habits we ask them to do every day.”

A superior clean is a smart investment in healthier mouths for life

Better brushing habits and healthier gums do more than improve everyday oral health. They can also help reduce the need for more intensive treatment over time. Oral health is connected to overall wellbeing, and prevention at home can help reduce future treatment needs, discomfort and cost over time. A P&G and American Academy of Family Physicians survey found that many people care about oral health, but very few spontaneously connect oral health with whole-body health, highlighting an opportunity to make daily oral care feel more like an act of prevention.

Prevention also matters for the environment. A peer-reviewed life cycle assessment published in the Journal of Dentistry found that managing advanced periodontal disease can be associated with up to approximately 10 times higher environmental impact compared with maintaining periodontal health through at-home prevention. The study also found that clinical interventions account for about 90% of total environmental impact across the modeled periodontal pathway, reinforcing prevention at home as an important lever for patients, healthcare systems and the environment.

“A superior clean is not just about how your teeth feel today,” said Svetlana Farrell, DDS, PhD, Sr. Director, Oral Health Sciences & Professional Scientific Relations. “By helping people remove more plaque, maintain healthier gums and support healthier mouths, Oral-B iO helps turn daily brushing into a simple habit that supports long-term oral health.”

Designed for real mouths and real brushing habits

Oral-B iO was designed around a simple truth: every mouth is different. Real mouths have curves, tight spaces, hard-to-clean molars and areas people often miss. Oral-B’s unique round head surrounds and adapts to each tooth, while advanced technology helps guide people to clean thoroughly yet gently, use the right pressure, and build better brushing habits.

For consumers, Oral-B iO makes a superior clean easier to achieve every day. For parents, Oral-B iO Kids helps make better brushing more engaging and easier to support. For dental professionals, Oral-B iO helps patients turn advice into action between visits.

Because when brushing well is harder than most people think, the best technology is the one that makes getting it right easier, every day. No wonder why Oral-B is the #1 toothbrush brand used and recommended by dentists worldwide and trusted by millions of consumers around the world.

About Oral-B

Oral-B® was founded in 1950 by a California periodontist, who invented an innovative toothbrush to help his patients achieve healthier teeth and gums at home. Oral-B® continues to stay true to his mission and is today the worldwide leader in the over $5 billion brushing market. Part of the Procter & Gamble Company, the brand manufactures electric toothbrushes and toothpaste for adults and children, oral irrigators, and interdental products.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit https://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at https://www.pg.com/news.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260911054017/en/

Permalink

https://www.aetoswire.com/en/news/1709202657390

Contacts

For more information please contact:

Cristina Morillogomez, morillogomez.c@pg.com

TOURISE Unveils 2027 Summit Under the Theme “Alliances That Move the World”

 RIYADH, Saudi Arabia - Thursday, 17. September 2026 AETOSWire Print 

Second global tourism summit to convene renowned leaders in Riyadh, March 23-25, 2027

First confirmed speakers announced, including leaders from Booking Holdings, Marriott, Hilton, Intrepid Travel and S4 Capital

Theme calls for new alliances across tourism, technology, investment and government to shape the sector’s next 50 years

 

(BUSINESS WIRE)--Under the patronage of His Royal Highness Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, His Excellency Ahmed Al-Khateeb, Minister of Tourism and Chairman of TOURISE, today announced the TOURISE 2027 Summit, taking place in Riyadh from March 23-25, 2027. Building on the inaugural TOURISE Summit in November 2025 and a year of collaboration since, the 2027 edition will run under the theme “Alliances That Move the World.” Over three days, leaders will focus on the partnerships, investments and actions needed to advance the global tourism agenda over the next 50 years.​

The Summit will convene public and private sector leaders across tourism, technology, investment, sustainability, culture, mobility and government to tackle the sector’s most pressing opportunities and challenges and help shape the next era of global tourism.​ At the inaugural Summit, TOURISE announced USD 113 billion in portfolio investments spanning hotels, integrated destinations, wellness, retail, talent development and AI-powered platforms, demonstrating the potential of public and private sector collaboration to translate ambition into investment and action.​

 

The first confirmed speakers for the 2027 Summit were also announced and include leaders from organizations such as Marriott, Wego, Switzerland Tourism and Technogym — with many more to come. Together, they represent organizations shaping how people travel, connect, invest and experience the world.​

TOURISE 2027 is also backed by a growing roster of partners and sponsors, including stc, Dar Al Arkan, The Avenues, Qiddiya City, Aseer Development Authority, Saudia, Jeddah Central, Taiba, Tourism Development Fund, Red Sea Global, Almosafer and Snapchat, reflecting the platform’s role in connecting public and private sector across the tourism value chain.

His Excellency Ahmed Al Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE, said:​

“The future of tourism will be shaped not by any single destination, company or institution, but by the strength of the alliances we build between the public and private sector. Saudi Arabia has seen firsthand what becomes possible when ambition, investment and partnership move together. Through TOURISE, we are taking that experience to the global stage, connecting leaders across sectors and markets to turn shared ambition into action. In March, we invite the world to Riyadh to build the alliances that will shape the next 50 years of tourism.”​

Gloria Guevara, President and CEO of the World Travel and Tourism Council, and panelist at today’s announcement, added:​

“The next chapter of tourism will be defined by collaboration at a scale we have never seen before. ‘Alliances That Move the World’ captures the opportunity before us: to connect industries, capital and ideas in ways that create meaningful progress for destinations, businesses and communities. TOURISE creates the space for leaders to move beyond discussion and work together on practical solutions for the future of travel.”​

TOURISE is backed by a Board of Trustees chaired by His Excellency, with global experts from online travel agencies, tour operators, hospitality, global tourism bodies, entertainment and media.​

Stakeholders interested in participating in the TOURISE 2027 Summit are encouraged to submit a request for an invitation and join the growing global community helping to shape the future of tourism.

Request an invitation here.

For the latest updates on speakers, research, partnership opportunities and Summit announcements, visit TOURISE.com.​

About TOURISE ​

TOURISE is the world’s premier platform for redefining and shaping the future of tourism. Created by the Saudi Ministry of Tourism, TOURISE launched in 2025, with its inaugural Summit taking place November 11-13 in Riyadh.​

A year-round global platform, TOURISE brings together leaders from government, business, investment, tourism and technology to turn bold ideas into action, unlock investment and help build a tourism sector that is sustainable, equitable and future-focused.​ This is where the next 50 years of tourism are shaped.​

For more information about TOURISE, visit TOURISE.com​

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916467896/en/

Permalink

https://www.aetoswire.com/en/news/54605693

Contacts

 

For further details contact: media@TOURISE.com

Beacon Acquires Haize Labs to Power AI for the Real Economy

 TORONTO & SAN FRANCISCO - Thursday, 17. September 2026 AETOSWire 

Haize Labs leadership will anchor Beacon’s new applied AI research group, accelerating the deployment of AI across the essential businesses Beacon owns

 

(BUSINESS WIRE)--Beacon Software (Beacon), the first centralized AI holding company, today announced that it has acquired Haize Labs, an AI reliability company that tests and safeguards AI agents for real-world deployment. The Haize Labs team will join Beacon to form its Applied AI Research Group, with co-founder and CEO Leonard Tang joining as VP of AI Research to lead the AI operating system that is deployed across Beacon’s companies.

Beacon believes that the fastest way to bring AI to the traditional economy is through the software businesses that essential industries already use and trust, equipping them with AI infrastructure. Beacon acquires these businesses for long-term growth and connects them to a centralized AI operating system that compounds with each additional acquisition and industry.

The addition of the Haize Labs team will strengthen this centralized technology platform, which provides shared engineering, AI, product and go-to-market capabilities to Beacon’s portfolio of 45 software companies with customers across recreation, utilities, education, government, manufacturing and other essential industries.

Key focuses for Beacon’s new Applied AI Research Group include: creating reusable AI infrastructure that compounds across Beacon’s portfolio without erasing the local context of each company; translating domain expertise into evaluation and feedback systems that define what good looks like in each business; building continuous testing, red teaming and observability for AI agents before and after deployment; and developing AI products that reduce administrative burden, improve customer service and help the portfolio businesses grow.

“Main Street businesses deserve access to the same caliber of AI talent and technology as the world’s largest companies,” said Nilam Ganenthiran, Founder and CEO of Beacon. “Haize Labs brings exceptional engineers to Beacon who know how to find where AI fails and make it better. Together, we’ll build AI our customers can count on, in the software they already use and trust.”

“The Fortune 500 will have no shortage of AI. The harder problem is making AI useful for the businesses that power the rest of the economy, where most humans work and receive value,” said Leonard Tang, Co-Founder and CEO of Haize Labs, who joins Beacon as VP of AI Research. “Haize Labs was founded with the mission of building AI that any business can depend on. Now, our work will be put directly to use for Beacon’s broad and growing portfolio of essential businesses.”

About Beacon

Beacon is the first centralized AI holding company. Beacon acquires software businesses serving customers across the traditional economy and equips them with AI infrastructure to help them grow. Beacon is building the world’s leading AI operating system that maps how companies operate, so the value compounds for the entire portfolio with each additional acquisition. The company is headquartered in Toronto, ON. Learn more at https://www.beaconholdings.com/.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917239094/en/

Permalink

https://www.aetoswire.com/en/news/1709202657402

Contacts

Media Contact

press@beaconsoftware.com

Thales Unveils HexaForce: AI-Powered, Sovereign Command and Control for NATO and Allied Nations

 Built on an open, interoperable architecture co-designed with armed forces, HexaForce was successfully tested during NATO CWIX 2026.

HexaForce is tailored for high-intensity warfare, supporting command requirements for over 100,000 personnel where operational tempo requires the extensive, targeted deployment of AI.

Thales’ multi-domain solution (covering land, sea, air, cyber, space, and information operations) is already available.

 

(BUSINESS WIRE)--Thales, a global leader in advanced technologies across Defence, Aerospace, and Cyber & Digital, has announced the launch of HexaForce, its next-generation AI-enhanced multi-domain command and control (C2) system. Purpose-built to support national sovereignty, HexaForce provides a rapid, battle-tested response to the massive growth in operational data and the accelerating pace of conflicts.

“Some armed forces require a dedicated data platform, while others need operational cross-domain interfaces to link up with allies and complete their systems, or faster multi-domain command functions leveraging state-of-the-art artificial intelligence. With HexaForce, Thales provides a sovereign solution tailored to each of these operational needs, setting a new benchmark in multi-domain C2 for NATO and allied nations amidst rising high-intensity conflicts.” — Christophe Salomon, Executive Vice-President, Secure Communications and Information Systems, Thales

1. A Multi-Domain Command and Control System

HexaForce operates seamlessly across all operational domains: land, air, sea, cyber, electromagnetic spectrum, space, and information operations. Featuring a resilient, distributed architecture, this platform orchestrates existing systems across national armed forces and coalitions to accelerate decision-making and secure operational advantage at every level of command.

2. Enhanced Capabilities Driven by cortAIx AI

HexaForce harnesses the artificial intelligence capabilities of cortAIx, Thales’ dedicated AI accelerator, which brings together 800 engineers and data scientists working in close alignment with the Group’s defence experts.

By integrating cutting-edge Large Language Models (LLMs) and agentic AI, HexaForce delivers tangible gains for operators across every phase of a mission:

Shorter planning cycles

Richer operational picture awareness

Real-time sharing and consolidation of tactical and operational situational pictures

Accelerated decision-making

Enhanced effector allocation

Optimised in-the-field maintenance and support.

By leveraging AI, HexaForce dramatically scales up data processing and operational intelligence. It automates the analysis, correlation, and prioritisation of massive data streams from military, open-source and civilian origins, significantly boosting military agility and tempo. Live trial phases are currently paving the way for full-scale deployment, targeting an increase in capacity from 100 to 1,000 targets processed per day.

This operational superiority draws directly on operational feedback from Artemis.IA—a data-centric platform deployed with the French Ministry of Armed Forces since 2023, which has proven its capability in multi-source data processing and AI scaling.

3. Seamless Integration from Tactical to Strategic Levels

HexaForce is currently the only market solution capable of orchestrating all assets across armed forces and coalition partners, spanning strategic commanders down to tactical units. It relies on a distributed data network designed to remain resilient even under severely degraded communications conditions.

4. Open and Interoperable Architecture

HexaForce combines a core software platform with multi-domain command applications. Built on open-source standards, its open and interoperable architecture has been rigorously tested, notably during the NATO CWIX 2026 exercise. This design ensures full sovereign control over incoming and outgoing data feeds without requiring data exposure.

HexaForce natively supports Data-Centric Security (DCS) and Federated Mission Networking (FMN) standards. Unlike closed, proprietary systems, it enables nations to integrate their chosen technology partners within a controlled, modular environment—delivering maximum operational performance alongside full national sovereignty. As an open, multi-domain solution, HexaForce provides complete C2 capabilities, including seamless connectivity with legacy systems provided by third-party vendors.

5. Co-developed with Frontline Forces

HexaForce is an agile milestone in military software development, built using short feedback loops alongside armed forces to continuously integrate end-user requirements at every stage.

About Thales

 

 

Thales (Euronext Paris: HO) is a global leader in advanced technologies for the Defence, Aerospace, and Cyber & Digital sectors. Its portfolio of innovative products and services helps address several major challenges: sovereignty, security, sustainability and inclusion.

 

 

The Group allocates €4.5 billion per year in Research & Development in key areas, particularly for critical environments, such as Artificial Intelligence, Cybersecurity, Quantum and Cloud technologies.

 

 

Thales has more than 85,000 employees in 65 countries. In 2025, the Group generated sales of €22.1 billion.

 

 

PLEASE VISIT

Thales Group

Thales

Recent images of Thales and its Defense, Aerospace and Cyber & Digital activities can be found on the Thales Media Library. For any specific requests, please contact the Media Relations team.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260917956437/en/

Permalink

https://aetoswire.com/en/news/1709202657384

Contacts

MEDIA CONTACT

Thales, relations médias

marion.bonnet@thalesgroup.com

+33(0)660384892

 

IFF Launches Omni-Bos™ PHY to Help Dairy Producers Get More Value from Feed

 New phytase technology unlocks nutrients already present in feed to improve efficiency, profitability and sustainability

(BUSINESS WIRE) -- IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today announced the launch of Omni-Bos™ PHY, a novel phytase enzyme designed specifically for dairy cattle. The technology helps producers improve nutrient utilization and feed efficiency by unlocking nutrients already present in feed, enabling cows to derive greater value from existing feed ingredients. Omni-Bos™ PHY will initially launch in the Middle East, Africa and Asia-Pacific regions.

“We believe the future of dairy nutrition is helping cows receive more value from the nutrients in their feed,” said Regina Cortada, vice president, Animal Nutrition & Health for IFF Health & Biosciences. “Our research challenged the long-held assumption that dairy cows fully utilize the phytate contained in feed. We found that phytate breakdown is often incomplete, leaving valuable nutrients unavailable to the animal. Omni-Bos PHY was developed to unlock those nutrients and help producers improve feed efficiency, support sustainability goals and increase profitability.”

Global milk production is projected to grow 2% annually over the coming decade, increasing pressure on producers to improve productivity while managing feed costs and sustainability targets. Feed remains one of the largest expenses in dairy production, making nutrient efficiency a critical opportunity for producers seeking to improve profitability and performance.

Phytate — a naturally occurring compound found in many feed ingredients — can bind nutrients and reduce their availability to the animal. While phytase technology has been widely used in poultry and swine production for decades, its effectiveness in dairy cattle has historically been limited.

“Traditional phytase enzymes were not designed to withstand the unique digestive conditions of dairy cattle,” said Ester Vinyeta, innovation director, Animal Nutrition & Health for IFF Health & Biosciences. “Omni-Bos PHY was specifically developed for ruminants and is designed to remain active where it can unlock nutrients that would otherwise remain inaccessible. This enables dairy producers to extract more nutritional value from existing feed ingredients while reducing nutrient losses.”

By helping cows utilize more of the protein, phosphorus and minerals already present in feed, Omni-Bos™ PHY can reduce reliance on supplemental phosphorus and protected amino acids while supporting the use of alternative protein sources. The result is improved feed efficiency, lower feed costs and reduced nitrogen and phosphorus excretion.

The enzyme is suitable for use in concentrates, premixes and total mixed rations and has been evaluated extensively throughout product development. In one study, Omni-Bos™ PHY decreased undegraded phytate in the abomasum by approximately 70% compared with a control diet. Additional studies in lactating dairy cows demonstrated that Omni-Bos™ PHY:

Improved phosphorus and phytate digestibility

Reduced nitrogen and phosphorus excretion

Increased digestibility of nutrients including crude protein and calcium

Collectively, these findings demonstrate Omni-Bos™ PHY’s ability to improve nutrient utilization and help dairy producers maximize the value of every ton of feed while supporting more sustainable production systems.

To learn more about Omni-Bos PHY, visit https://www.iff.com/animal-nutrition/products/omni-bos-phy

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent and biosciences, we’re innovating for the future. We deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2026 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, ℠ or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916599752/en/

Permalink

https://aetoswire.com/en/news/1709202657391

Contacts

Paulina Heinkel

VP, Branding and Communication for IFF Health & Biosciences

media.request@iff.com

Galderma’s Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing

ZUG, Switzerland - Wednesday, 16. September 2026


    Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121
    Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1
    These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3

 

(BUSINESS WIRE)--Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its Restylane hyaluronic acid (HA) injectables portfolio in China, one of the world's fastest-growing aesthetics markets, through evidence generation that supports broader patient access and additional treatment areas.1-3

Powered by diverse NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.1,4-8 Restylane Volyme is a moderately soft and flexible gel made with OBT that distributes within the tissue to offer natural-looking results, helping to soften temple hollowing, restore facial balance, and create a refreshed appearance.1,4,9 With a dual-layer patent-pending technique leveraging both needle and cannula, Restylane Volyme enables healthcare professionals to provide precise, customized, and safe product placement in line with each patient’s aesthetic goals10-12

The volume of the temples can diminish with age, which can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance.12-14 These facial changes can be accelerated in people undergoing medication-driven weight loss, a phenomenon which has increased rapidly in recent years.12-14 Following the launch of Restylane Volyme in China for the treatment of the mid-face region, this study provides new evidence supporting its effectiveness and safety for correction of temple hollowing, in a market where there are currently limited options.1

“Temple hollowing is a common concern among patients seeking facial rejuvenation, particularly for those experiencing medication-driven weight loss, yet treatment options in China remain limited. These results demonstrate that Restylane Volyme can provide effective, natural-looking correction with high levels of patient satisfaction and a robust safety profile. As demand for individualized aesthetic treatments continues to grow in China, expanding the range of evidence-based solutions available will be increasingly important.”

PROF. ZHAO HONGYI
STUDY PRINCIPAL INVESTIGATOR,
DIRECTOR & CHIEF OF THE DEPARTMENT OF PLASTIC SURGERY, BEIJING HOSPITAL, CHINA

In this randomized, evaluator-blinded study, 162 adults were recruited across six sites in China and were split 2:1 into two groups; the Restylane Volyme treatment group or the no treatment control group.1 Results showed that for patients in the Restylane Volyme group:

    Strong effectiveness
        94.4% of patients demonstrated at least 1-grade improvement in temple hollowing, from baseline, in both temples at Month 6 after last treatment, compared to just 2.0% in the control group at Month 6 after baseline.1
        Blinded-evaluator Galderma Temple Volume Deficit Scale responder rates remained high through Month 121
        91.3% of patients showed improvement on the Global Aesthetic Improvement Scale for both temples through Month 12, according to the treating investigator1
    High satisfaction
        Patient satisfaction was high at Month 3 and remained consistently high, with more than 84% of patients satisfied with both the natural look and natural feel of their temples through Month 121
        More than 90% said they would recommend the treatment to a friend, and over 86% would have the treatment again1
        Half of the participants felt comfortable returning to social engagement within 24 hours after initial treatment1
    Robust safety
        Restylane Volyme was generally well tolerated, with no treatment-related serious adverse events and no granulomas1

“These positive topline results further strengthen the clinical evidence supporting Restylane Volyme and mark an important step in our strategy to expand the Restylane portfolio in China. As one of the world’s fastest-growing aesthetics markets, China presents a significant opportunity to address evolving patient needs with science-backed, differentiated solutions. This study supports our ambition to broaden the indications available to practitioners and patients, while reinforcing Galderma’s leadership in Injectable Aesthetics through continued investment in innovation and clinical research.”

BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.
GLOBAL HEAD OF R&D
GALDERMA

With over 30 years of innovation and more than 77 million treatments administered worldwide, the Restylane portfolio offers a versatile range of HA gels that remain highly relevant in responding to today’s most significant aesthetic trends and needs.15-16 China is one of the fastest growing aesthetics markets worldwide and HA fillers are among the top 10 most-sold aesthetics products.2,3 This study highlights Galderma’s commitment to expand the availability of its Restylane portfolio to more patients and practitioners in China and exemplifies its continuing expansion in a growing and strategically significant market.

About the Restylane portfolio
Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.17-19 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.5,20,21 Powered by NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.4,6-8 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results. 18,22,23 Approved indications vary by market.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References

    Galderma. Data on file. 43CH2401
    Deloitte. China Aesthetic Medicine Outlook Report. Accessed September 2026. Available online.
    Grand View Horizon. China Aesthetic Medicine Market Size & Outlook, 2026-2033. Accessed September 2026. Available online
    Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´ including Restylane SHAYPE).
    Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
    Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.
    Öhrlund Å, et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.
    Belmontesi M, et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.
    Talarico S et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41(12):1361-9. doi: 10.1097/DSS.0000000000000549
    Restylane® Volyme. IFU. Available online. Accessed September 2026
    Galderma Laboratories, L.P. Data on file. MA-63365 Study Report. 2025
    Galderma. Data on file. Restylane Contour temple investigator closeout meeting executive summary. 2025
    Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg, 2023;39:719-73. doi: 10.1055/a-2148-6321
    Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS.2023;81-97-98. doi: 10.1016/j.bjps.2023.04.057
    Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.
    Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis
    Restylane® EU Instructions for Use. July 2026.
    Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
    Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.
    Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.
    Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
    Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.
    Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.1320

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260915734207/en/

Permalink
https://www.aetoswire.com/en/news/1609202657354

Contacts

For further information:

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

Schneider Electric Concludes Innovation Summit Middle East & Africa, Highlights Energy Intelligence as the Next Phase of the Energy Transition

 Abu Dhabi, United Arab Emirates -

As AI, electrification and industrial expansion reshape energy demand across the Middle East and Africa, Schneider Electric today concluded Innovation Summit Middle East & Africa by positioning energy intelligence as the next phase of the energy transition - where infrastructure becomes more connected, resilient and software-defined.

Held at ADNEC in Abu Dhabi, the two-day summit convened over 2,500 attendees, including government leaders, industry analysts, customers, partners, students, and media, under the theme ‘Advancing Energy Tech to Power Intelligence and Resilience.’

Industry leaders explored how electrification, AI-ready data centers, cybersecurity, and digital innovation are reshaping energy systems. Day one featured keynotes from H. E. Abdullah bin Touq Al Marri, UAE Cabinet Member and Minister of Economy and Tourism, and Schneider Electric CEO Olivier Blum, in the presence of H.E. Marie Audouard, Ambassador Extraordinary and Plenipotentiary of the French Republic to the UAE. The summit also featured the launch of the Innovation Hub, the Data Cube, and Olivier Blum’s address on “The Era of Intelligence.”

“We’re entering an Era of Intelligence in which AI is becoming embedded in the physical economy. AI may be digital, but it runs on electricity and depends on the physical systems beneath it,” said Olivier Blum, CEO of Schneider Electric. “As an Energy Technology Partner, we help customers connect energy and operations through data, software, AI and automation, turning intelligence into action to improve performance, resilience and competitiveness. The scale of this shift is clear in the Middle East and Africa, where governments and businesses are investing in energy and digital infrastructure to support industrial transformation and long-term growth.”

The summit also featured the release of the company’s 2026 Industrial AI in CPG Study for the UAE, which found that 59% of UAE manufacturers expect transformational AI adoption by 2030, compared with 42.2% globally. Walid Sheta, President, MEA Zone, said, “As our region’s manufacturers move faster and more confidently on industrial AI than anywhere else, it’s our responsibility to make sure that confidence is well-founded. Cybersecurity, resilience, and return on AI investment are the concerns we hear about most often from customers, and rightly so.”

Schneider Electric reaffirmed its commitment to collaborating with governments, customers, and partners to accelerate intelligent, resilient energy infrastructure.

Permalink

https://www.aetoswire.com/en/news/1609202657358

Contacts

Press contact:

Mohammed Abdulla

mabdulla@apcoworldwide.com

www.se.com

Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth

 MOUNTAIN VIEW, Calif. - Wednesday, 16. September 2026 AETOSWire  

AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trials

Rubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle

 

(BUSINESS WIRE) -- Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind.

RLS-1496 has already demonstrated efficacy in clinical trials for actinic keratoses and aging skin, and other skin conditions such as psoriasis and atopic dermatitis, generating novel human evidence demonstrating the dual SenoAdaptive mechanism that clears pathologic senescent cells and promotes a redox reset by modulating NRF2 pathways in stressed aged cells, including stem and progenitor cells. Ex vivo studies on a human hair follicles AGA model resulted in the restoration of hair follicle growth, as depicted in the image above.

In an independent ex vivo human AGA model — conducted using intact human hair follicles from male patients with AGA, challenged with dihydrotestosterone (DHT) to replicate the follicular miniaturization environment seen in AGA patients — RLS‑1496 demonstrated statistically and highly statistically significant increases in hair follicle elongation compared to vehicle control at 2 doses, respectively, with the highest dose showing a numerically greater trend in mean elongation than finasteride.

Hair follicle elongation at Day 6 was greater with RLS-1496 versus vehicle across all doses, with the strongest effect at the highest concentration — directionally outperforming standard-of-care finasteride

The pattern is consistent with rescue of the anagen (active growth) phase, when targeting senescent cells from the follicular niche allows stem cell reactivation from the dormant state and the follicle to resume its natural growth program

“The senescent cell biology underlying hair follicle aging is compelling, deeply consistent with what we have seen across our RLS-1496 program, and vastly underexplored as a therapeutic target,” said Rubedo Chief Executive Officer Frederick Beddingfield III, MD, PhD, FAAD. “For the first time, we are bringing a medicine into the clinic designed to clear the aged cells at the root of stem cell dormancy and follicular miniaturization. We are proud to do so in partnership with Dr. Pariser, and we are moving with the same urgency that made RLS-1496 the world’s first GPX4 modulator in human trials.”

AGA is the most prevalent form of hair loss globally, affecting approximately 50 million men and 30 million women in the U.S. alone; however, the treatment landscape has seen no genuinely new FDA-approved approaches in nearly 30 years.2 The global AGA market, valued at $3.2 billion in 2025 and projected to reach $6.8 billion by 2035, is defined by two therapies — minoxidil and finasteride — that slow the hormonal signals that cause hair follicles to progressively shrink and degenerate, a process known as follicular miniaturization. Follicular miniaturization is the biological hallmark of AGA, in which each successive growth cycle produces a thinner, shorter hair until the follicle can no longer produce visible hair. Neither therapy addresses the senescent — aged and dysfunctional — cells now understood to accumulate within the follicular niche and drive this miniaturization at the cellular level.3,4,5

Unlike existing therapies that target secondary hormonal causes of hair loss, RLS-1496 is designed to act on the primary cellular aging mechanism: the accumulation of senescent and stressed dermal papilla cells that actively suppress stem cells, follicular regeneration, and drive progressive miniaturization. By targeting these cells with selective elimination or functional restoration, depending on the cell state, RLS-1496, a first-in-class SenoAdaptive Drug, aims to remove the cellular brake on follicular regeneration itself.3,4,5,6

Rubedo Co-Founder and Chief Scientific Officer Marco Quarta, PhD, will present the ex vivo data, along with additional RLS-1496 data, at the 13th Annual Aging Research & Drug Discovery (ARDD) Meeting at Harvard University, October 1–3, 2026 — the world’s largest dedicated longevity science conference. The presentation marks the first time a GPX4 modulator program in hair loss will be presented at a major longevity science conference.

Dr. Quarta said, “RLS-1496 appears to act at several convergent points in the AGA disease cascade — where we believe it acts by clearing senescent cells, suppressing follicular regeneration, reducing inflammatory SASP signaling, while also modulating NRF2 pathways and activating Wnt/β-catenin pathways governing anagen re-entry. To our knowledge, no approved AGA therapy operates at this level of biology.”

Rubedo’s proprietary ALEMBIC™ spatial transcriptomics applied to patient hair follicle biopsies identified senescence markers and transcriptomic signals consistent with activation of the follicular regenerative cascade, including the expansion of hair follicle progenitors, and downregulation of key drivers of the follicle regression phase — providing human clinical evidence that RLS-1496’s effects on senescent cell biology extend to hair follicle tissue. In preclinical animal studies, RLS-1496 also achieved approximately 32% greater hair regrowth versus vehicle.1,6,7

“The preliminary data we have seen with RLS-1496 are scientifically intriguing and warranted clinical evaluation,” said Dr. Pariser, Professor of Dermatology at Eastern Virginia Medical School and Principal Investigator of Virginia Clinical Research, Inc., who will be leading the RLS-1496 hair loss clinical trial. “The senescence biology underlying AGA is increasingly well-supported in the published literature, and RLS-1496 represents a genuinely novel approach to it. I look forward to seeing what the data show in patients given the ongoing unmet need.”

About RLS-1496 and GPX4 Modulation

Rubedo’s lead candidate RLS-1496, being developed for topical and oral administration, is a first-in-class, disease-modifying GPX4 modulator selectively targeting pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases. These include immunology and inflammation (I&I), dermatology and skin aging, hair loss, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative disease.

In certain pathologic cells, aging is associated with an imbalance in GPX4. Modulation of GPX4 sensitizes cells to ferroptosis, which is a type of programmed cell death and is believed to be an Achilles heel of senescent cells. By modulating GPX4 in ferroptosis-sensitive senescent “aged” cells, RLS-1496 may be able to clear these cells to fight disease and also support healthy cells to function properly and restore tissue homeostasis. Beyond its targeted senolytic function in triggering selective ferroptosis within pathological senescent cells, RLS-1496 can also act as a restorative modulator that induces a vital ‘redox-reset’ through a controlled hormetic response in stressed neighboring cells, effectively clearing the source of chronic inflammation while actively re-establishing healthy tissue homeostasis. This dual-action mechanism represents a novel drug category—Adaptive SenoTherapeutics.

RLS-1496 uses Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™, which identifies targets within pathologic senescent cells and develops selective cellular rejuvenation medicines for these targets.

About Rubedo Life Sciences

Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders, including hair loss. Our lead drug candidate – RLS-1496, a potential first-in-class disease-modifying GPX4 modulator – is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Mountain View, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.

References

Rubedo Life Sciences. RLS-1496 demonstrates hair follicle elongation in a DHT-challenged ex vivo androgenetic alopecia model. Data on file. 2026.

Global Market Insights. Androgenetic Alopecia Treatment Market Size, Share & Trends Analysis Report. 2026

Bahta AW, Farjo N, Farjo B, Philpott MP. Premature Senescence of Balding Dermal Papilla Cells In Vitro Is Associated with p16(INK4a) Expression. Journal of Investigative Dermatology2008;128(5):1088-1094. doi: 10.1038/sj.jid.5701147

Yang YC, Fu HC, Wu CY, Wei KT, Huang KE, Kang HY. Androgen Receptor Accelerates Premature Senescence of Human Dermal Papilla Cells in Association with DNA Damage. PLoS ONE2013;8(11): e79434. doi: 10.1371/journal.pone.0079434

Upton JH, Hannen RF, Bahta AW, Farjo N, Farjo B, Philpott MP. Oxidative Stress-Associated Senescence in Dermal Papilla Cells of Men with Androgenetic Alopecia. Journal of Investigative Dermatology 2015;135(5):1244-1252. doi: 10.1038/jid.2015.28

Pappalardo A, Kim JY, Abaci HE, Christiano AM. Restoration of hair follicle inductive properties by depletion of senescent cells. Aging Cell2024;24: e14353. doi: 10.1111/acel.14353

Rubedo Life Sciences. RLS-1496 achieves 32% greater hair regrowth versus vehicle in preclinical animal studies. Data on file. 2026.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916811892/en/

Permalink

https://www.aetoswire.com/en/news/1609202657361

Contacts

Investor Contact: Ali Siam, Chief Business Officer alisiam@rubedolife.com | 781-974-9559

Media Contact: Peter Collins, TogoRun p.collins@togorun.com | 908-499-1200

NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence

 New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments

 

(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond.

“NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infrastructure will help us deliver a more seamless and connected experience for our Krewe at games and across the digital platforms that we use.”

This partnership launches following the Buccaneers first regular 2026 season game against the Cincinnati Bengals on September 13. The partnership expands NetApp’s relationship with the NFL as the league’s Official Intelligent Data Infrastructure Partner, helping to securely manage, protect, and activate the data behind the league’s operations. Across the NFL, NetApp technology supports demanding real-world workloads, including the storage and availability of game day video used by NFL football operations and club football operations teams. This collaboration has demonstrated how the right infrastructure can help complex, data-intensive organizations operate more efficiently and resiliently.

By using NetApp Keystone, a flexible and simple subscription-based service that adapts to changing business needs, the Buccaneers can accelerate data workloads with industry-leading performance, intelligent data management, and high availability across data centers and cloud environments. The NetApp Platform delivers built-in data security that autonomously detects threats and enables rapid recovery.

“Successful teams achieve meaningful results long before game day by bringing together the right people, trusted data, sound decisions, and disciplined execution,” said Gabie Boko, Chief Marketing Officer at NetApp. “Elite sports show what organizations can accomplish when their people can turn information into confident action. As a Proud Partner of the Tampa Bay Buccaneers, we’re celebrating the preparation, trust, and teamwork that sustain excellence and the Intelligent Data Infrastructure that helps make it possible.”

Additional Resources

NetApp and the NFL Team Up with Intelligent Data Infrastructure

The Unseen MVP of the NFL Season

NetApp Named Presenting Partner of 2026 NFL Madrid Game

NetApp Data Platform Powers Data Operations for Super Bowl LX

About the Tampa Bay Buccaneers

The Tampa Bay Buccaneers are in their 51st season as members of the National Football League and compete in the National Football Conference’s South Division. They were purchased by the late Malcolm Glazer in 1995 and are currently owned by the Glazer Family. Established in 1976, the Buccaneers have totaled 10 division titles, two conference championships and two Super Bowl Championships, including Super Bowl LV that was played on their home field at Raymond James Stadium. The Buccaneers have also been leaders in the NFL in fan engagement, earning a record 12 consecutive No. 1 rankings in overall customer satisfaction in the league’s annual Voice of the Fan survey. Additionally, the franchise is very active in the community, with the Tampa Bay Buccaneers Foundation, the Glazer Vision Foundation and the Glazer Family Foundation. For more information, visit www.buccaneers.com.

About NetApp

For more than three decades, NetApp has helped the world’s leading organizations navigate change – from the rise of enterprise storage to the intelligent era defined by data and AI. Today, NetApp is the Intelligent Data Infrastructure company, helping customers turn data into a catalyst for innovation, resilience, and growth.

At the heart of that infrastructure is the NetApp data platform – the unified, enterprise-grade, intelligent foundation that connects, protects, and activates data across every cloud, workload, and environment. Built on the proven power of NetApp ONTAP, our leading data management software and OS, and enhanced by automation through the AI Data Engine and AFX, it delivers observability, resilience, and intelligence at scale.

Disaggregated by design, the NetApp data platform separates storage, services, and control so enterprises can modernize faster, scale efficiently, and innovate without lock-in. As the only enterprise storage platform natively embedded in the world’s largest clouds, it gives organizations the freedom to run any workload anywhere with consistent performance, governance, and protection.

With NetApp, data is always ready – ready to defend against threats, ready to power AI, and ready to drive the next breakthrough. That’s why the world’s most forward-thinking enterprises trust NetApp to turn intelligence into advantage.

Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260916768662/en/

Permalink

https://aetoswire.com/en/news/1609202657360

Contacts

Media Contact:  

Kenya Hayes  

NetApp  

kenya.hayes@netapp.com  

Investor Contact:  

Kris Newton  

NetApp  

kris.newton@netapp.com